SAN FRANCISCO, Feb. 11, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will webcast an analyst and investor conference call with a urothelial cancer specialist and company management on Friday, February 15, 2019 at 2:00 p.m. Pacific Time, during the 2019 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (GU), which will be held February 14-16, 2019 at Moscone West in San Francisco, CA. The event will follow a presentation of preliminary efficacy, safety and immune monitoring data from the ongoing urothelial carcinoma patient cohort in the PIVOT-02 study evaluating bempegaldesleukin* (NKTR-214) in combination with nivolumab.
Analyst Call with Urothelial Cancer Specialist:
Date and Time: Friday, February 15, 2019 at 2:00 p.m. Pacific Time
Dial-in: 877-881-2183 (toll-free) or 970-315-0453 (international)
Passcode: 9688945
The conference call will include PIVOT-02 investigator Arlene O. Siefker-Radtke, M.D., Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center and Clinical Co-leader of the Bladder Cancer SPORE Executive Committee. The webcast and slides for the conference call can be accessed through a link that is posted on the Investors section of the Nektar website at https://ir.nektar.com/events-and-presentations/events. The web broadcast of the conference call will be available for replay through March 15, 2019.
Details on the Data Presentation at ASCO-GU:
Abstract Title: NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02
Abstract #: 388
Presenter: Arlene O. Siefker-Radtke, M.D., The University of Texas MD Anderson Cancer Center
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, Testicular, and Adrenal Cancers
Poster Board: G1
Date and Time: Friday, February 15, 2019, 12:15-1:45 p.m. and 5:15-6:15 p.m. Pacific Time
About Nektar
Nektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at www.nektar.com.
* rINN
Contact:
For Investors:
Jennifer Ruddock of Nektar Therapeutics
415-482-5585
- or -
Ashleigh Barreto of Nektar Therapeutics
628-895-0694
SOURCE Nektar Therapeutics
